Patents by Inventor Matthias Olbrich

Matthias Olbrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7947705
    Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: May 24, 2011
    Assignee: Biotie Therapies GmbH
    Inventors: Norbert Höfgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
  • Publication number: 20070161671
    Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
    Type: Application
    Filed: March 6, 2007
    Publication date: July 12, 2007
    Inventors: Nobert Hofgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
  • Patent number: 7211583
    Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: May 1, 2007
    Assignee: Elbion AG
    Inventors: Nobert Höfgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
  • Publication number: 20070009998
    Abstract: The invention relates to a process for the production of (R)- or (S)-8-chloro-6-hydroxyoctanoic acid alkyl esters of the general formula (R)-II or (S)-II, in which R means C1-4 alkyl, from 8-chloro-6-oxo-octanoic acid alkyl esters of the general formula I, in which R has the above meaning. The desired enantiomers are produced biocatalytically in an enantioselective reduction, wherein as desired the strains Mucor racemosus are used for (S)-II compounds and Geotrichum candidum for (R)-II compounds. The resultant esters may, in known manner, be converted stereospecifically into (R)-?-lipoic acid.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 11, 2007
    Applicant: VIATRIS GMBH & CO., KG
    Inventors: Matthias Olbrich, Rainer Gewald
  • Patent number: 7135328
    Abstract: The invention relates to a process for the production of (R)- or (S)-8-chloro-6-hydroxyoctanoic acid alkyl esters of the general formula (R)-II or (S)-II, in which R means C1-4 alkyl, from 8-chloro-6-oxo-octanoic acid alkyl esters of the general formula I, in which R has the above meaning. The desired enantiomers are produced biocatalytically in an enantioselective reduction, wherein as desired the strains Mucor racemosus are used for (S)-II compounds and Geotrichum candidum for (R)-II compounds. The resultant esters may, in known manner, be converted stereospecifically into (R)-?-lipoic acid.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: November 14, 2006
    Assignee: Viatris GmbH & Co. KG
    Inventors: Matthias Olbrich, Rainer Gewald
  • Publication number: 20040224971
    Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
    Type: Application
    Filed: April 16, 2004
    Publication date: November 11, 2004
    Inventors: Nobert Hofgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
  • Publication number: 20030180896
    Abstract: The invention relates to a process for the production of (R)- or (S)-8-chloro-6-hydroxyoctanoic acid alkyl esters of the general formula (R)-II or (S)-II, 1
    Type: Application
    Filed: January 27, 2003
    Publication date: September 25, 2003
    Inventors: Matthias Olbrich, Rainer Gewald
  • Patent number: 6486124
    Abstract: The invention relates to formulations of cyclosporin with high bioavailability for oral administration, which contain about 1 part by weight of one or more cyclosporin(s), preferably cyclosporin A and/or cyclosporin G, 7.5 to 7.8 parts by weight of one or more polyethylene glycol esters of saturated C10-C22hydroxy fatty acids, 0.7 to 0.85 part by weight of a monohydric alcohol as co-solvent, and 0.7 to 0.8 part by weight of a polyhydric alcohol as co-solvent. The drug form is produced by initially dissolving the cyclosporin in ethanol and, while stirring, adding propylene glycol and SOLUTOL® HS 15 until a clear, viscous solution results, bottled as drinkable solution or packed into capsules.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: November 26, 2002
    Assignee: Novartis AG
    Inventors: Matthias Olbrich, Heinrich Potter
  • Publication number: 20020025927
    Abstract: The invention relates to formulations of cyclosporin with high bioavailability for oral administration, which contain about 1 part by weight of one or more cyclosporin(s), preferably cyclosporin A and/or cyclosporin G, 7.5 to 7.8 parts by weight of one or more polyethylene glycol esters of saturated C10-C22 hydroxy fatty acids, 0.7 to 0.85 part by weight of a monohydric alcohol as co-solvent, and 0.7 to 0.8 part by weight of a polyhydric alcohol as co-solvent. The drug form is produced by initially dissolving the cyclosporin in ethanol and, while stirring, adding propylene glycol and SOLUTOL® HS 15 until a clear, viscous solution results, bottled as drinkable solution or packed into capsules.
    Type: Application
    Filed: October 17, 2001
    Publication date: February 28, 2002
    Inventors: Matthias Olbrich, Heinrich Potter